Patents by Inventor Shinta Kobayashi
Shinta Kobayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965180Abstract: Provided is a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. A human cancer tissue was repeatedly grown in a NOG mouse, separated cancer cells from the grown cancer tissue, and tested and compared various cancer cell culture processes. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process.Type: GrantFiled: August 14, 2020Date of Patent: April 23, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Patent number: 11858987Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: GrantFiled: June 26, 2020Date of Patent: January 2, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20230230986Abstract: A solid-state imaging element according to the present disclosure includes a first light receiving pixel, a second light receiving pixel, and a metal layer. The first light receiving pixel receives visible light. The second light receiving pixel receives infrared light. The metal layer is provided to face at least one of a photoelectric conversion unit of the first light receiving pixel and a photoelectric conversion unit of the second light receiving pixel on an opposite side of a light incident side, and contains tungsten as a main component.Type: ApplicationFiled: April 14, 2021Publication date: July 20, 2023Applicant: SONY SEMICONDUCTOR SOLUTIONS CORPORATIONInventors: Yoshiaki MASUDA, Kazuyoshi YAMASHITA, Shinichiro KURIHARA, Syogo KUROGI, Yusuke UESAKA, Toshiki SAKAMOTO, Hiroyuki KAWANO, Masatoshi IWAMOTO, Takashi TERADA, Sintaro NAKAJIKI, Shinta KOBAYASHI, Chihiro ARAI
-
Publication number: 20230085803Abstract: An objective of the present invention is to provide non-human animal models of cancer pathology, which mimic the hierarchical organization, cancer progression process, or biological property of human cancer tissues, and uses thereof. To achieve the objective described above, first, the present inventors transplanted cells of NOG-established cancer lines into NOG mice and morphologically observed the resulting tissue organization. As a result, the non-human animal models were demonstrated to exhibit pathologies (the hierarchical organization, cancer progression process, or biological properties of the cancer cells) similar to that of human cancer. Specifically, the present inventors succeeded in preparing non-human animal models exhibiting pathologies more similar to a human cancer, and cell culture systems using NOG-established cancer cell lines where the in vitro cell morphology is more similar to that of human cancer.Type: ApplicationFiled: November 22, 2022Publication date: March 23, 2023Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Masami Suzuki, Koichi Matsubara, Atsuhiko Kato, Chie Kato, Shinta Kobayashi, Yu Jau Chen, Masaki Yamazaki
-
Patent number: 11536713Abstract: An objective of the present invention is to provide non-human animal models of cancer pathology, which mimic the hierarchical organization, cancer progression process, or biological property of human cancer tissues, and uses thereof. To achieve the objective described above, first, the present inventors transplanted cells of NOG-established cancer lines into NOG mice and morphologically observed the resulting tissue organization. As a result, the non-human animal models were demonstrated to exhibit pathologies (the hierarchical organization, cancer progression process, or biological properties of the cancer cells) similar to that of human cancer. Specifically, the present inventors succeeded in preparing non-human animal models exhibiting pathologies more similar to a human cancer, and cell culture systems using NOG-established cancer cell lines where the in vitro cell morphology is more similar to that of human cancer.Type: GrantFiled: December 24, 2010Date of Patent: December 27, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masami Suzuki, Koichi Matsubara, Atsuhiko Kato, Chie Kato, Shinta Kobayashi, Yu Jau Chen, Masaki Yamazaki
-
Publication number: 20220221472Abstract: It has been discovered that plasma samples from endometriosis patients contain a number of markers whose abundance is different from those in healthy individuals. It has also been discovered that, by measuring the abundance of those markers, whether or not a subject is affected by endometriosis can be diagnosed, the extent of endometrial fibrosis or adhesion in a subject can be determined, pain of a patient affected or suspected of being affected by endometriosis can be predicted, and pathological conditions of the patient can be monitored.Type: ApplicationFiled: April 24, 2020Publication date: July 14, 2022Inventors: Shinta KOBAYASHI, Kohji NAGANO, Hiroshi OHMORI, Ayako KAKIUCHI, Ryo KONNO, Tadashi SANKAI
-
Patent number: 11124773Abstract: The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.Type: GrantFiled: October 6, 2011Date of Patent: September 21, 2021Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Patent number: 10934351Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: GrantFiled: February 12, 2016Date of Patent: March 2, 2021Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20200385686Abstract: The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.Type: ApplicationFiled: August 14, 2020Publication date: December 10, 2020Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Publication number: 20200325222Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: ApplicationFiled: June 26, 2020Publication date: October 15, 2020Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Patent number: 10018630Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.Type: GrantFiled: September 7, 2012Date of Patent: July 10, 2018Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, PHARMALOGICALS RESEARCH PTE. LTD.Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20160159904Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: ApplicationFiled: February 12, 2016Publication date: June 9, 2016Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20140314675Abstract: An objective of the present invention is to provide: a cancer stem cell isolated using a cell marker; a substantively homogeneous cancer stem cell population including said cancer stem cell; and a method of preparing said cancer stem cell population. Another objective of the present invention is to provide: a method for separating cancer stem cells with a high proliferative potential and those with a low proliferative potential; a method for inducing cancer stem cells to have a different proliferative potential; and cancer stem cells separated or induced by these separation or induction methods. A further objective of the present invention is to provide: a method of screening for pharmaceuticals using said cancer stem cell or cancer stem cell population; a method for detecting the presence of said cancer stem cell or cancer stem cell population and for identifying or quantifying the same.Type: ApplicationFiled: September 7, 2012Publication date: October 23, 2014Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20140302511Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective of the present invention is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.Type: ApplicationFiled: October 26, 2012Publication date: October 9, 2014Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
-
Publication number: 20130288248Abstract: The purpose of the present invention is to provide: a cancer stem cell mass from which cells incapable of forming cancer are substantially removed and which has a characteristic property of reproducing a layered structure of a cancer tissue; a process for producing the cancer stem cell mass; and use of the cancer stem cell mass. For achieving the purpose, the present inventors grew a human cancer tissue repeatedly in a NOG mouse, separated cancer cells from the grown cancer tissue, and made a comparison of various cancer cell culture processes with each other. As a result, a cancer stem cell composition which is homogeneous and is substantially free of the coexistence of cells capable of forming cancer and cells incapable of forming cancer in a mixed state can be produced successively by employing an attached culture process using a serum-free stem cell culture medium rather than a generally employed floating culture process, and consequently the present invention has been accomplished.Type: ApplicationFiled: October 6, 2011Publication date: October 31, 2013Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, PHARMALOGICALS RESEARCH PTE. LTD.Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Yu Jau Chen, Atsuhiko Kato, Masami Suzuki, Koichi Matsubara
-
Publication number: 20130019327Abstract: An objective of the present invention is to provide non-human animal models of cancer pathology, which mimic the hierarchical organization, cancer progression process, or biological property of human cancer tissues, and uses thereof. To achieve the objective described above, first, the present inventors transplanted cells of NOG-established cancer lines into NOG mice and morphologically observed the resulting tissue organization. As a result, the non-human animal models were demonstrated to exhibit pathologies (the hierarchical organization, cancer progression process, or biological properties of the cancer cells) similar to that of human cancer. Specifically, the present inventors succeeded in preparing non-human animal models exhibiting pathologies more similar to a human cancer, and cell culture systems using NOG-established cancer cell lines where the in vitro cell morphology is more similar to that of human cancer.Type: ApplicationFiled: December 24, 2010Publication date: January 17, 2013Inventors: Masami Suzuki, Koichi Matsubara, Atsuhiko Kato, Chie Kato, Shinta Kobayashi, Yu Jau Chen, Masaki Yamazaki